European Journal of Pharmacology

Recurrent hypoglycemia increases cognitive impairment in diabetes mellitus patients. Following cerebral neuron injury, endothelial cells provide morphological, metabolic and immune support to damaged neurons. We investigated the inflammatory mechanism involved in hippocampal neuron degeneration. Behavioral experiments, including the open field test (OFT) and the Morris water maze test, were performed to measure cognitive changes. Using a vascular ring experiment, we evaluated vasodilation of the carotid artery. ZBP1 expression was knocked down after transfection with small interfering RNA in a brain endothelial cell line (bEnd3). In this study, PANoptosis, a recently defined form of programmed cell death (PCD), was found to be increased by hypoglycemia in the hippocampus of type 2 diabetic mice in vivo and by low glucose in bEnd3 cells in vitro. ZBP1 knockdown decreased PANoptosis induced by low-glucose stimulation in high-glucose-cultivated bEnd3 cells. RNA transcriptomics sequencing revealed that AGE-RAGE signaling significantly changed after ZBP1 was knocked down in bEnd3 cells. Corresponding biochemical data confirmed that ZBP1 knockdown regulated the advanced glycation end products (AGEs)-Receptor for Advanced Glycation End Products (RAGE) axis in bEnd3 cells. We present the first evidence that hypoglycemia impaired cognition in mice with type 2 diabetes by activating brain endothelial ZBP1-mediated PANoptosis via the AGE-RAGE axis. ARTICLE HIGHLIGHTSO_LIPANoptosis, a newly defined form of programmed cell death, is induced in the hippocampus after recurrent hypoglycemia in male db/db mice. C_LIO_LIZBP1, a sensor of the PANoptosome, was activated in low glucose cultured brain endothelial cells. C_LIO_LIHypoglycemia impairs vasodilation and cognitive function in type 2 diabetic mice. C_LIO_LIOur study indicates that inhibiting ZBP1-PANoptosis and the AGE-RAGE axis may be a potential approach to prevent hypoglycemia-induced cognitive degeneration in individuals with type 2 diabetes. C_LI

Diabetes Mellitus (DM) is a rapidly increasing disease around the world. It is known that DM is associated with numerous complications which affect life quality by its debilitating nature. DM is associated with cognitive impairment and neurodegeneration, partly driven by neuroinflammation and disrupted neuronal signalling. Incretin-based treatments have recently been suggested to exert potential effects on the central nervous system in diabetic patients. However, the triple agonist of GIP/GLP-1/GCG Retatrutides effects on cognition under diabetic conditions remain unexplored. This study aims to reveal whether impaired cognitive performance, such as learning and memory, is ameliorated by Retatrutide treatment in diabetic rats, together with associated metabolic, inflammatory and histological changes. Male Sprague-Dawley rats were allocated to four groups: control (C), streptozotocin-induced diabetic (STZ), streptozotocin-induced diabetic rats treated with Retatrutide (STZR), and sham rats treated with Retatrutide alone (R). DM was induced by streptozotocin injections. Spatial learning and memory were assessed using the Morris Water Maze and Passive Avoidance tests. Metabolic parameters were monitored, while neuroinflammatory markers (IL-1{beta}, TNF-), neurotrophic-related gene expression (BDNF, CREB, AKT), Tau protein levels, and histopathological changes in the cortex and hippocampus were evaluated using molecular, biochemical, and histological analyses. Streptozotocin-induced diabetes resulted in persistent hyperglycaemia, total body weight loss, impaired learning and memory. Retatrutide treatment reduced blood glucose levels without achieving a full euglycaemia or preventing weight loss. Behavioural tests showed that Retatrutide treatment preserved spatial learning and short-term memory compared to untreated animals. These effects were accompanied by attenuation of neuroinflammatory responses, particularly reduced TNF- levels, trends toward preserved neurotrophic-related transcriptional profiles, and partial maintenance of cortical and hippocampal structural integrity. Retatrutide alone did not enhance cognitive performance beyond control levels. These findings support the hypothesis that triple agonists may exert beneficial effects on cognitive performance under diabetic conditions. Retatrutide alleviates DM-associated cognitive impairment in streptozotocin-induced diabetic rats and is associated with reduced neural inflammatory burden and protected neuroanatomical structure. The observed cognitive benefits appear to extend beyond metabolic regulation alone. Further studies in models more closely reflecting type 2 diabetes are warranted to clarify the underlying mechanisms and translational relevance.

BackgroundStroke remains a leading cause of mortality worldwide. Ischemic stroke, caused by arterial occlusion, induces sensorimotor deficits and memory impairments. Excessive activity of the brain angiotensin II type 1 receptor (AT1R) is associated with hypertension and cerebral ischemia. Candesartan (CN), an AT1R blocker, improves cerebrovascular blood flow. Pomegranate (Punica granatum) is rich in polyphenolic antioxidants that reduce oxidative stress and inflammation, suggesting potential neuroprotective effects in cerebral ischemia. AimThis study compared the neuroprotective effects of CN administered alone or in combination with pomegranate (POM) in a rat model of cerebral ischemia induced by chronic unilateral carotid artery ligation. MethodsCerebral ischemia was induced by ligation of the right common carotid artery (RCCA) in adult rats. Animals were randomly assigned to four groups: sham control, untreated ischemic, ischemic treated with CN, and ischemic treated with CN + POM. Sensorimotor and cognitive functions were assessed 1-15 days post-surgery using beam balance (BB), beam walking (BW), modified sticky-tape (MST), novel object recognition (NOR), and the Morris water maze (MWM) tests. ResultsRCCA ligation induced marked sensorimotor deficits and memory impairments. Both CN monotherapy and CN + POM treatment equally restored sensorimotor function to sham-control levels, as demonstrated by BB, BW, and MST tests. In contrast, CN + POM treatment showed greater efficacy than CN alone in improving short-term recognition and spatial memory, as demonstrated by NOR and MWM performance. ConclusionCN effectively reverses ischemia-induced sensorimotor deficits, whereas the addition of POM confers specific and enhanced protection against cognitive impairment, indicating distinct mechanisms underlying sensorimotor and memory recovery after cerebral ischemia.

Background: Deep brain stimulation (DBS) is a treatment option for Parkinson disease (PD). However, the effect of DBS on the arterial pressure (AP) remains unexplored. We aimed to develop an artificial baroreflex system for treating orthostatic hypotension (OH) due to central baroreflex failure in patients with PD. To achieve this, we developed an appropriate algorithm after estimating the dynamic responses of the AP to DBS using a white noise system identification method. Methods: We randomly performed DBS while measuring the AP tonometrically in 3 trials involving 3 patients with PD treated with DBS. We calculated the frequency response of the AP to the DBS using a fast Fourier transform algorithm. Finally, the feedback correction factors were determined via numerical simulation. Results: The frequency responses of the systolic AP to random DBS were identifiable in all 3 trials, and the steady state gain was 8.24 mmHg/STM. Based on these results, the proportional correction factor was set to 0.12, and the integral correction factor was set to 0.018. The computer simulation revealed that the system could quickly and effectively attenuate a sudden AP drop induced by external disturbances such as head-up tilting. Conclusion: An artificial baroreflex system with DBS may be a novel therapeutic approach for OH caused by central baroreflex failure.

IntroductionDrug repurposing offers a cost-effective and time-efficient strategy for cancer therapy by leveraging existing drugs with established safety profiles, thus functioning as an alternative therapeutic strategy in demanding diseases such as cancer. Antidiabetic agents, in particular, have demonstrated encouraging anticancer potential. Among them, the non-sulfonylurea insulin secretagogue repaglinide (RPG) has shown emerging anticancer potential, yet its effects on breast and lung cancers remain largely unexplored. Thus, this study investigates the anticancer activity of repaglinide in human breast (MCF-7) and lung (A549) cancer cell lines, focusing on its cytotoxic, pro-apoptotic, anti-proliferative, and anti-migratory effects and the underlying possible molecular mechanisms. Methodology and ResultsMTT cytotoxic assay revealed that RPG reduced cell viability in a dose-/time-dependent manner, with an IC (48h) of 100.8 {+/-} 3.98 {micro}M for MCF-7 and 104 {+/-} 3 {micro}M for A549. Further, the apoptotic effect of RPG on both cell lines was evidenced by double staining assays, comet assay, and western blotting analysis, suggesting that RPG explicitly caused DNA damage and activated intrinsic and extrinsic apoptosis pathways. Additionally, RPG suppressed clonogenicity and enforced G1 arrest in MCF7 and A549 cells by modulating cell cycle regulations as well as cell proliferation pathways. Moreover, RPG markedly suppressed cell motility, as demonstrated by scratch and Transwell migration/invasion assays, which is correlated with reduced MMP-2 and MMP-9 expression, confirmed by gelatin zymography and western blotting. ConclusionConclusively, Repaglinide exerts potent anticancer effects in breast and lung cancer cells by modulating key oncogenic signaling pathways, and thus can be considered a promising candidate for repurposing in cancer therapy.

Endogenous circadian oscillators regulate learning, cognitive performance and memory are disrupted due to circadian shifts. High-fat-high-fructose (H) diet, photoperiodic shifts induced chronodisruption (CD) and a combination (HCD) causes neurobehavioral perturbations wherein; the merits of exogenous melatonin in alleviating the said behavioral deficits are studied herein. Indices of anxiety (marble burying test, elevated plus maze test and hole board test) and depressive behavior (sucrose preference test, forced swim test and tail suspension test) were elevated in H, CD and HCD groups. Significant increments in the titres of thyroid hormone levels (T3, T4 and TSH) and mRNA levels of hippocampal pro-inflammatory genes (Tnf-, Il-1{beta}, Il-4, Il-6, Il-10, Il-12, Il-17, Mcp-1 and Nf-{kappa}b) in the said experimental groups corroborates with the said changes. Exogenous melatonin treatment to the said experimental groups viz. HM, CDM and HCDM; accounted for moderate to significant improvement in the said neurobehavioral perturbations and hippocampal inflammatory markers. Hippocampal BDNF-TrkB pathway genes of H, CD and HCD had recorded a non-significant downregulation in mRNA but without prominent changes in proteins. Likewise, melatonin-treated groups showed moderate to significant improvement in transcripts of Bdnf, Trkb, Nt-3, Nt-4, Psd-95 and Syn-1. Herein, we report neurobehavioral perturbations caused by a combination of H and CD. Melatonin-mediated improvement in neurobehavior and the corrective changes in hippocampal BDNF-TrkB pathway implies towards the potential anxiolytic and anti-depressive activity as reported herein.

Parkinsons disease (PD) is the second most progressive degenerative disorder of the brain due to dopaminergic (DA) neuron degenerations and alpha-synuclein (-Syn) accumulations. At present, the disease has no effective treatment. Therefore, the current study objective is to identify a novel anti-PD formula (Zhi-Shi-Huang-Wu Formula, F-2) computed at 8:4:2:1 ratio from HSP 70 promoter activators Valeriana jatamansi (V), Acori talarinowii (A), Scutellaria baicalensis (S), Fructus Schisandrae (F). Traditionally, V is used to cure memory impairments, A treats mental disorders, and chronic mild stress, S for neuroprotection, and F showed multiple therapeutic actions to treat insomnia. This study investigated the neuroprotective potential of the V, A, S, F, formula F-2 and its underlying molecular mechanisms in transgenic Caenorhabditis elegans models. A, S, F, and F-2 successfully restored 6-hydroxydopamine intoxicated DA neuron degenerations, reduced food-sensing behavior disabilities, and attenuated -Syn aggregations. Moreover, activates the lipid deposition and proteasome expressions to confirm -Syn degradations at the cellular level. Reactive oxygen species (ROS) cause oxidative stress, and A, S, F, and F-2 repressed ROS and raised SOD-3 expressions. Overall, these data indicate that V, A, S, F combined into F-2 (22.3%) are more effective against PD progression-like symptom than individual drugs V (0.7%), A (11.4%), S (9.6%), and F (12.6%). These improved neuroprotective actions of F-2 possibly due to following the antioxidative pathway. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=144 SRC="FIGDIR/small/709540v1_ufig1.gif" ALT="Figure 1"> View larger version (47K): org.highwire.dtl.DTLVardef@1a6f1f7org.highwire.dtl.DTLVardef@157a270org.highwire.dtl.DTLVardef@69a238org.highwire.dtl.DTLVardef@1194b5e_HPS_FORMAT_FIGEXP M_FIG C_FIG

Mitochondrial pyruvate carrier (MPC) inhibition was found protective in models of neurodegenerative diseases, such as Alzheimers and Parkinsons. However, little is known about MPC as a potential therapeutic target in Huntingtons disease (HD), a neurodegenerative disorder with dysregulation of the pro-survival pathway integrated stress response (ISR). Here, we investigate if MPC inhibition modulates the ISR and mitigates mutant huntingtin (mut-Htt) proteotoxicity in a cellular HD model. We treated cells expressing N-terminal fragments of wild-type- (wt-) or mut-Htt with two MPC inhibitors (mitoglitazone and UK5099) or solvent control. Metabolism was assessed analysing resazurin reduction, oxygen consumption, extracellular acidification, and ATP levels. ISR activation and huntingtin proteostasis were assessed using western-blot and filter-trap assays. Mut-Htt-expressing cells showed decreased resazurin reduction and ATP levels, and increased eIF2 phosphorylation, indicating metabolic stress and ISR activation. MPC inhibitors (100 {micro}M) increased resazurin reduction and decreased respiration. The latter was rescued by the membrane-permeant methyl pyruvate, which bypasses MPC inhibition. In wt-Htt-expressing cells, MPC inhibitors increased levels of ATP and ISR markers, suggesting metabolic adaptation and ISR activation. In mut-Htt-expressing cells, MPC inhibitors preserved ATP levels and attenuated mut-Htt-induced eIF2 phosphorylation but without changing soluble or aggregated mut-Htt levels. This work showed that MPC inhibition differentially modulates the ISR: it activates ISR in control cells and attenuates overactive ISR in mut-Htt-expressing cells. However, MPC inhibition did not impact the proteostasis of N-terminal fragment mut-Htt. Further studies are essential to explore MPC inhibition in less severe full-length mut-Htt-expressing models to better understand its therapeutic potential in HD.

BackgroundThe primary cause of death associated with opioids is opioid-induced respiratory depression (OIRD). Naloxone is used to reverse OIRD, but this drug is a competitive antagonist of {micro}-opioid receptor (MOR) and reverses analgesia, which limits its therapeutic use. Alternative non-opioid receptor antagonist-based approaches to OIRD treatment and prevention are needed. The aim of this study was to evaluate if setmelanotide (SET) is capable of reversing OIRD in a mouse model. MethodsC57BL/6J male and female mice and Sprague-Dawley rats were given IP morphine or fentanyl and then treated 15 min later with either SET or vehicle VEH (IP) in a random order. Breathing was recorded by barometric plethysmography, and pain sensitivity was measured by the tail-flick test. ResultsIn mice with OIRD, SET induced a 3-fold reduction of the apnea index, and decreased apnea duration as compared to the VEH treatment. SET increased respiratory rate and did not affect opioid-induced analgesia. Photostimulation of MC4R+ ChR2-expressing fibers in the parafacial region of MC4R-Cre mice elicited short-latency excitatory postsynaptic current in rostral ventral respiratory group (rVRG) pre-motoneurons projecting to the phrenic nucleus in the C3-C4 ventral horns of the spinal cord. Fentanyl inhibited the activity of rVRG neurons and SET reversed this effect. ConclusionsSET effectively treated OIRD by increasing respiratory rate and inducing a significant decrease in the number of apneas without decreasing analgesia.

BackgroundWhen the skin wound defect is too large, it is difficult for the body to heal itself, and medical treatment is often needed. How to shorten the healing cycle and reduce the incidence of infection is a difficult problem faced by clinicians. Panax notoginseng(PN), a traditional Chinese medicine, can promote the absorption of inflammatory exudates, granulation tissue formation and epidermal proliferation, effectively inhibit the inflammatory reaction of wounds and promote the healing of skin wounds, but its molecular mechanism has not been fully clarified so far. Based on network pharmacology and animal experiments, this study explored the target and molecular mechanism of PN in the treatment of skin wound. MethodsThe active components and potential targets of PN were obtained from the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) and UniProt database, and the skin wound-related targets were obtained from the GeneCards database. The intersecting targets were filtered using Venny 2.1.0. The intersecting targets were imported into the STRING database to construct a protein-protein interaction (PPI) network. Cluster analysis was performed using the MCODE and CytoHubba plugins in Cytoscape 3.8.2 to obtain core functional network modules and the top 10 key target genes. The intersecting targets were subjected to KEGG and GO enrichment analysis using the DAVID 6.8 database (https://david.ncifcrf.gov/). The component-target-pathway network of PN in the treatment of skin wounds was constructed using Cytoscape 3.8.2 software. In the experimental verification phase, 48 Sprague-Dawley (SD) rats were randomly divided into a control group and a PN group, with 24 rats in each group. A full-thickness skin excision was performed to establish a wound model. The PN group received intraperitoneal injections of the drug, while the control group received an equivalent amount of saline. Wound area measurements were taken on days 1, 4, and 7 after model establishment. Histopathological changes in the injured area and the expression and localization of TNF-, IL-6, and IL-10 were observed through hematoxylin and eosin (HE) staining and immunohistochemical staining. Relative expression levels of the three factors were detected using quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA). ResultsThis study identified 8 major active components, 156 targets, and 115 signaling pathways involved in the treatment of skin wounds in rats using PN. The top 10 core target genes included TNF, IL-6, and IL-10, primarily enriched in signaling pathways such as NF-{kappa}B, MAPK, and JAK-STAT. Animal experiments revealed that at 4 and 7 days post-injury, the wound area in the PN group was significantly smaller than that in the control group (P<0.05). HE staining showed reduced infiltration of neutrophils and inflammatory cells in the injury area at 7 days in the PN group, accompanied by more pronounced fibroblast proliferation and collagen secretion. Molecular detection indicated that TNF-, IL-6, and IL-10 positive reactants were mainly distributed in the cytoplasm and matrix of epidermal cells, inflammatory cells, and fibroblasts in the skin. qRT-PCR and ELISA results showed that TNF- expression in the PN group was significantly lower than that in the control group at 4 and 7 days (P<0.01). IL-6 expression was lower than that in the control group at all time points, peaking at 4 days and then decreasing (P<0.01). IL-10 expression was significantly lower than that in the control group at 1 and 7 days (P<0.01). ConclusionPN exhibits characteristics such as multi-component, multi-target, multi-pathway synergy, and multiple regulatory pathways in the treatment of skin wounds. It can reshape the dynamic balance of cytokine networks, including TNF-, IL-6, and IL-10, optimize the temporal progression of "inflammation initiation - repair transition - tissue remodeling", and provide a therapeutic effect of "efficient debridement - orderly repair - low scar risk" for skin wounds. It is one of the ideal natural drugs for regulating skin wound healing.

{beta}-Carotene is a strong antioxidant and immunomodulator, but it breaks down in the presence of oxygen and isnt readily bioavailable. Nutrishield(R) {beta}-Carotene is a special starch-based microencapsulation system designed to protect {beta}-carotene from oxidation, make it easier to spread in the gastrointestinal environment, and improve its effectiveness. This study reported Nutrishield(R) as a formulation platform by using {beta}-carotene as a model compound. We compared how well it worked in vitro and in vivo with {beta}-carotene that wasnt encapsulated. We randomly put thirty-two male BALB/c mice into four groups (n=8): Control, LPS, LPS + {beta}-Carotene (10 mg/kg/day), and LPS + Nutrishield(R) (the same dose of {beta}-Carotene). After an intraperitoneal injection of LPS (1 mg/kg, twice weekly), the treatments were administered orally for 28 days. LPS administration significantly elevated TNF- (142 {+/-} 8 pg/mL), IL-6 (118 {+/-} 7 pg/mL), and serum 8-OHdG (5.4 {+/-} 0.3 ng/mL) in comparison to controls (TNF- = 62 {+/-} 5 pg/mL; IL-6 = 51 {+/-} 4 pg/mL; 8-OHdG = 2.1 {+/-} 0.2 ng/mL). Nutrishield(R) {beta}-Carotene supplementation significantly normalized cytokine profiles (TNF- = 69 {+/-} 4 pg/mL; IL-6 = 56 {+/-} 3 pg/mL; IL-10 increased from 38 {+/-} 2 to 76 {+/-} 3 pg/mL; p < 0.001 vs. LPS). Histological analysis demonstrated reduced hepatocellular vacuolation and renal tubular degeneration in the Nutrishield(R) {beta}-Carotene group relative to the {beta}-carotene and LPS groups. These findings demonstrate that Nutrishield(R) microencapsulation significantly enhances the functional antioxidant and anti-inflammatory efficacy of {beta}-carotene in a murine model of systemic inflammation. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=134 SRC="FIGDIR/small/711625v1_ufig1.gif" ALT="Figure 1"> View larger version (48K): org.highwire.dtl.DTLVardef@1da9828org.highwire.dtl.DTLVardef@3b8ef2org.highwire.dtl.DTLVardef@25e339org.highwire.dtl.DTLVardef@168e793_HPS_FORMAT_FIGEXP M_FIG C_FIG

Chronic pain is associated with neuropsychiatric comorbidities characterized by impairments in cognitive and behavioral flexibility, yet the direct impact of chronic pain on reward-guided behavior remains poorly understood. Here, we investigated how chronic neuropathic pain altered sucrose-reinforced behavior across multiple behavioral assays with distinct cognitive-behavioral demands in male and female mice. Mice underwent spared nerve injury (SNI) or sham surgery and were tested in operant sucrose self-administration, reversal learning, and extinction training. The impact of acute painful stimulation on sucrose seeking was also assessed. SNI produced stable mechanical hypersensitivity without affecting acquisition or extinction of sucrose self-administration, indicating intact baseline acquisition and sucrose seeking. In contrast, chronic neuropathic pain selectively altered behavioral flexibility: SNI females exhibited faster acquisition of reversal learning, while SNI mice as a group showed impaired inhibition of responding on the previously reinforced lever during early reversal. Acute painful stimulation suppressed sucrose seeking in males, but not in females, independent of chronic pain status. At the neural level, painful mechanical stimulation differentially modulated medial prefrontal cortex (mPFC) activity, increasing infralimbic c-Fos expression in SNI mice while decreasing it in sham controls relative to non-stimulated animals. There was no evidence of chronic mPFC hyperactivity as indexed by {Delta}FosB expression. Together, these findings demonstrate that chronic neuropathic pain did not globally disrupt sucrose reward-related behavior, but instead selectively altered behavioral flexibility and pain-reward interactions in a sex-dependent manner, with accompanying alterations in mPFC engagement following aversive stimulation.

BackgroundMetabolic-dysfunction associated steatotic liver disease(MASLD) is a global epidemic affecting >30 % global population with no approved therapies till date. Recent reports suggest that activation of NLRP3 inflammasome may be involved in the pathogenesis of MASLD. We, therefore, aimed to identify small molecule inhibitor(s) of NLRP3 inflammasome as a potential therapeutic strategy to manage MASLD and validate their efficacy using in vitro and in vivo models of MASLD. MethodologyWe screened an in-house library of natural products using an in vitro phenotypic assay and identified a gut microbiota derived metabolite of dietary Tryptophan; indole-3 acetic acid (I3A) for its ability to inhibit the levels of IL-1{beta} and IL-18, which are elevated as a result of activation of NLRP3 inflammasome in differentiated THP1 cells. Subsequently, we carried out several in vitro and in vivo studies to confirm the mechanism of action of I3A and its ability to mitigate the key hallmarks of MASLD ResultsOur in vitro data suggest that I3A is an inhibitor of NLRP3 inflammasome. I3A was also found to improve the blood glucose level, plasma lipid profile, hepatic fat, and liver function in high-fat-high-fructose diet induced model of MASLD using C57BL/6 mice. ConclusionOur results show that I3A, which has been previously reported to be a gut microbiota-derived metabolite of dietary tryptophan, mitigates the key hallmarks of MASLD in an NLRP3 dependent manner. A dedicated structure-activity-relationship (SAR) study around the I3A chemotype may be carried out in future to identify novel NLRP3 inhibitors with desirable pharmacological profile.

Epilepsy is one of the most prevalent neurological diseases, with 25-33% of patients developing drug-resistant epilepsy (DRE). The precise etiology of DRE remains unidentified. Recent studies have revealed an increase in tetraploid astrocytes in drug-resistant temporal lobe epilepsy (DR-TLE), a common subtype of DRE. This study aims to characterize the function of tetraploid astrocytes in the brain of subjects without central nervous system diseases and in DR-TLE. Cortical samples adjacent to the epileptogenic zone were obtained from DR-TLE patients undergoing resective neurosurgery and from postmortem donors without neurodegenerative, neurological, or psychiatric disorders. Tetraploid astrocytes were identified using the astrocytic marker NDRG2, and their functional characterization was assessed by evaluating markers of metabolism (ALDH1L1), transport (SOX9), electric function (NF1A), or reactive astrocytes (NF{kappa}B p65 and pSTAT3), via immunostaining followed by flow cytometry. Tetraploid astrocytes expressed all functional markers tested. The percentage of tetraploid astrocytes expressing ALDH1L1 or SOX9 was significantly increased in DR-TLE with respect to controls, whereas NF1A remained unchanged. Inflammatory markers pSTAT3 and NF{kappa}B p65 showed an upward trend in 4C astrocytes. In contrast, diploid (2C) astrocytes expressing these markers were reduced in DR-TLE, suggesting a functional shift toward polyploid cells in the DR-TLE cortex. Our findings suggest the preservation of markers of metabolism, transport and electric function in tetraploid astrocytes in physiological conditions and in DR-TLE patients. Moreover, the astrocytes with metabolic and transporter markers were significantly increased in DR-TLE. These findings point to tetraploid astrocytes as potential contributors to DR-TLE mechanisms.

Background: Clinical evidence on the contemporary management and functional outcomes of patients with Wernicke encephalopathy remains limited. This study aimed to clarify the nationwide patterns of thiamine administration and functional outcomes at discharge. Methods: Using the Japanese nationwide inpatient Diagnosis Procedure Combination database, we identified patients hospitalized with Wernicke encephalopathy between July 2010 and March 2024. Initial intravenous thiamine doses were categorized as low ([&le;]300 mg/day), medium (301-900 mg/day), or high (>900 mg/day). Outcomes included in-hospital mortality and functional status (Barthel Index) at discharge. Results: We identified 7856 patients with Wernicke encephalopathy. Over the 13-year study period, the proportion of patients receiving initial high-dose thiamine increased markedly from 5.4% to 49.0%, while the frequency of low-dose therapy decreased from 83.0% to 37.9%. Despite prompt intervention [median time to initial administration: 0 days (interquartile range, 0 to 0 days)], 56.1% of patients were discharged with impaired activities of daily living (Barthel Index <90), and the in-hospital mortality rate was 3.8%. Conclusions: High-dose thiamine treatment is increasingly implemented for Wernicke encephalopathy in Japan. Although in-hospital mortality was relatively low, the high prevalence of functional impairment at discharge, despite early treatment initiation, indicates substantial burden of Wernicke encephalopathy. Given the limited clinical evidence, further research investigating the optimal thiamine dose and develop effective primary prevention strategies for Wernicke encephalopathy is needed.

Amyotrophic Lateral Sclerosis (Lou Gehrigs disease) is a progressive neurodegenerative disease affecting hundreds of thousands of people worldwide. It is characterized by the degeneration of the neurons in the brain and spinal cord of the patients, leading to a loss of control of muscles. Over time, without nerves to stimulate them muscles tend to atrophy. ALS may occur sporadically or run in families; many mutations have been identified for the latter. Treatment of ALS is mostly limited to three approved therapeutic agents: riluzole, edaravone, and tauroursidiol/ sodium phenylbutyrate. Among these, riluzole remains the most effective despite its early discovery. There are no conclusive meta-analysis comparing riluzole monotherapy to all possible co-therapies present. In this work we have attempted to address such a concern and observed that no adjunct therapy significantly improved the performance of riluzole. However, mitochondrial/ oxidative stress modulator and neuroimmune/ neuroexcitability modulator co-therapy exhibited positive trends. Surprisingly, trials were mainly confined to the USA and European countries, indicating unequal demographic representation in ASL research. We have concluded that large double blinded inter-continental RCTs to be carried out for better understanding of the scenario.

BackgroundOur study aimed to investigate the relationship between phenotypic age acceleration (PAA), bowel dysfunction (constipation, diarrhea), and depression severity, and examine whether phenotypic age acceleration can play a mediating role in bowel dysfunction and depression severity. MethodsThe data analysis of our study was conducted from the National Health and Nutrition Examination Survey (2005-2010). Participants with bowel dysfunction were identified on the questionnaire of bowel health. Depression was determined based on the Patient Health Questionnaire-9 (PHQ-9). The calculation of PAA is based on 9 test indicators and actual age; a higher PAA means accelerated aging. In this study, a weighted linear regression model was used to analyze the associations among defecation disorders, PAA, and depression. Restricted Cubic Spline (RCS) curves were applied to explore the potential non-linear relationships between the aforementioned variables. Additionally, a mediation effect model was employed to verify whether PAA could function as a mediating variable in the relationship between defecation disorders and depression. ResultA total of 11,808 participants were included in this study. Linear regression analysis showed that both diarrhea ({beta}=3.73, 95% Confidence Interval (CI): 1.69-8.22, P=1.60x10-3) and depression severity ({beta}=1.08, 95%CI: 1.06-1.09, P=4.61x10-16) were positively correlated with PAA. In addition, both constipation ({beta}=2.76, 95%CI: 1.89-4.04, P=2.28x10-6) and diarrhea ({beta}=4.29, 95%CI: 2.65-6.95, P=2.11x10-7) were positively correlated with depression severity. Further mediation effect analysis revealed that PAA may play a mediating role in the association between diarrhea and depression severity (the proportion of mediation effect in the total population was 7.2285%). When exploring whether PAA exerts a mediating role in the association between constipation and depression severity, it was found that PAA played a mediating role in female participants and participants aged <60 years, except for male participants and those aged [&ge;]60 years (the proportion of mediation effect was 9.8417% in females and 8.4512% in the population aged <60 years, with all relevant P-values <0.005)

Polyunsaturated fatty acids (PUFAs) are fundamental for different cellular and structural processes, especially regarding the nervous system. However, its incorporation in food has many bioaccessibility limitations, making it important to find new ways of its consumption. In this work, nanoencapsulated PUFAs orally administrated to C57BL/6 elite male mice for 8 weeks showed better bioavailability when compared to administration of free acids, also improving the effects on dentate gyrus neuronal survival as well as on the proneurogenic elements of the Brain derived neurotrophic factor biological pathway also in the hippocampus. In addition, nanoencapsulated PUFAs increased expression of Fabp5, a relevant n-3 fatty acids transporter in the brain. Altogether, our results would mean that the form of administration of the fatty acids can alter not only how much and how preserved they reach the central nervous system, but also have a differential impact in the diverse processes they contribute to.

BackgroundMyocardial Infarction (MI) remains a leading cause of mortality worldwide, despite advancements in clinical therapies and interventions. MI results from prolonged ischemia, leading to hypoxia-induced damage to cardiac tissue and reperfusion-injury (R/I) that aggravates cardiomyocyte (CM) loss. One key cellular event during this process is accumulation of dysfunctional mitochondria, resulting from environmental hypoxia and subsequent oxidative stress upon reperfusion. Post-MI cardiac-remodeling involves changes in both cellular and extracellular matrix (ECM). Ubiquitin-dependent and independent autophagy are crucial for cardio protection during this phase. The ECM provides structural integrity and functions as a reservoir for signaling molecules. Asporin (ASPN), a small leucine-rich proteoglycan, plays a role in modulating cardiac-remodeling by limiting excessive fibrosis and protecting CMs from cell death. MethodsWe investigated the therapeutic potential of ASPN by using an exogenous recombinant peptide of ASPN (rASPN), testing its effects using an in-vitro ischemia-reperfusion (I/R) model simulating MI conditions. Two I/R models were developed using an immortalized human embryonic cardiac cell line to reflect the hypoxia-reperfusion (H/R) phases of MI. In the No-Reoxygenation (No-ReOx) model, cells were subjected to hypoxia for 18 hours, with or without exogenous rASPN. In the Reoxygenation (ReOx) model, cells underwent 18 hours of hypoxia, then 12 hours of reoxygenation (simulating reperfusion), with or without rASPN. ResultsProteomics revealed that ASPN modulates key pathways involved in apoptosis, non-canonical autophagy, and metabolic reprogramming. Additionally, ASPN influenced immune response pathways and significantly affected TGF-{beta} signaling, a central mediator of cardiac fibrosis and remodeling post-MI. These findings indicate that ASPN plays a multifaceted role in regulating cellular responses to hypoxia and R/I. ConclusionsOur H/R model simulates key aspects of MI and R/I. The protective role of ASPN observed in this model suggests it as a promising candidate for developing cardioprotective therapies to minimize R/I and adverse cardiac-remodeling following MI.

The hexanucleotide repeat expansion (GGGGCC) in the C9orf72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The C9orf72 protein forms a complex with SMCR8 and WDR41 (CSW), which acts as a GTPase-activating protein (GAP) regulating small GTPases like ARF1 and RABs involved in intracellular trafficking. Although these findings implicated the ARF1 dysregulation in ALS/FTD and the critical need for validation of its inhibition as potential intervention, small molecules that target the interactions between CSW and ARF1 are lacking. In this study, we showed that the tyrosine-phosphorylated form (Tyr-782) of ASAP1, an ARF-GAP that inactivates ARF1, is increased in the motor cortex of both sporadic ALS and ALS with C9orf72 mutations. Overexpression of C9orf72 led to Golgi disorganization, partially mimicking the effects of ARF1 inhibitor brefeldin A on dispersion of Golgi apparatus. To identify a better strategy to enhance C9orf72 and ARF1 interactions, we applied rational design and virtual screening of a 40-million compound library of small molecules targeting the ARF1-CSW interface. Molecular docking, MM-GBSA binding energy, ADME/Tox profiles, and interaction analysis established MCULE-5095997944 as a top candidate for ARF1 modulation. MCULE-5095997944 demonstrated strong binding to ARF1 in the nanomolar range, reduced GTP-bound ARF1 levels upon ARF1 activation, and altered ARF1-dependent Golgi organization. These studies identified the first small molecule targeting ARF1-CSW interaction and further support ARF1 modulation as a potential therapeutic approach for ALS/FTD.